|
TAMPA, FL--(Marketwired - August 04, 2015) - Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. (OTCQB: OXIS) and (EURONEXT PARIS: OXI.PA) announced today the execution of the amendment to its current exclusive option agreement with the University of Pittsburgh related to certain patent rights developed by Dr. Xiang-Qun Xie, Associate Dean for Research Innovation and Professor, Pharmaceutical Sciences, School of Pharmacy. The patent rights relate to the addition of certain novel compositions-of-matter which could prove useful as therapeutics for the treatment of various human diseases. |
